Coagulant Therapeutics

Developer of therapeutic drugs intended for the treatment of acute bleeding and related indications. The company’s drugs offer an optimized, proprietary rFVIIa molecule, termed CT-001, for the prevention and treatment of acute bleeding and other coagulation cascade-related diseases and leverages expertise in biologics and the coagulation cascade to develop novel therapeutics targeted to treat acute bleeding and adjacencies, enabling doctors to treat traumatic injury and save the lives of many young people.